GAMMA Investing LLC Has $1.56 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

GAMMA Investing LLC increased its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 1,722.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 104,715 shares of the company's stock after buying an additional 98,969 shares during the period. GAMMA Investing LLC's holdings in Takeda Pharmaceutical were worth $1,557,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Blair William & Co. IL grew its holdings in Takeda Pharmaceutical by 8.1% during the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after purchasing an additional 913 shares during the last quarter. Vise Technologies Inc. grew its holdings in Takeda Pharmaceutical by 3.1% during the fourth quarter. Vise Technologies Inc. now owns 34,635 shares of the company's stock valued at $459,000 after purchasing an additional 1,026 shares during the last quarter. Sage Rhino Capital LLC grew its holdings in Takeda Pharmaceutical by 14.9% during the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock valued at $157,000 after purchasing an additional 1,538 shares during the last quarter. Vident Advisory LLC grew its holdings in Takeda Pharmaceutical by 13.5% during the fourth quarter. Vident Advisory LLC now owns 13,606 shares of the company's stock valued at $180,000 after purchasing an additional 1,616 shares during the last quarter. Finally, OLD Mission Capital LLC grew its holdings in Takeda Pharmaceutical by 13.7% during the fourth quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock valued at $185,000 after purchasing an additional 1,687 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

TAK stock traded down $0.19 during midday trading on Friday, hitting $15.20. 2,391,339 shares of the company traded hands, compared to its average volume of 1,956,500. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.43. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The business has a 50 day simple moving average of $14.71 and a 200-day simple moving average of $14.16. The stock has a market capitalization of $48.37 billion, a price-to-earnings ratio of 38.00, a price-to-earnings-growth ratio of 0.24 and a beta of 0.23.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). The company had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.